XML 64 R42.htm IDEA: XBRL DOCUMENT v3.6.0.2
Summary of Significant Accounting Policies - Additional Information (Detail)
€ in Millions
 12 Months Ended
Jul. 18, 2014
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2016
EUR (€)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Jul. 01, 2013
USD ($)
Summary Of Significant Accounting Policies [Line Items]            
Deferred revenue   $ 3,419,000        
Net revenue - commercial product sales   $ 1,895,000        
Cash discount as incentive for prompt payment   2.00%        
Deferred revenue from sale of raw insulin   $ 1,800,000        
Deferred cost related to sale of raw insulin   $ 0        
Maturity period of cash equivalents   90 days or less at the time of purchase 90 days or less at the time of purchase      
Inventory charge   $ 200,000   $ 39,300,000    
Percentage of credit exchange receivable   65.00% 65.00%      
Prepaid expenses and other current assets   $ 4,364,000   4,018,000    
Other income (expense)   (597,000)   1,366,000 $ 1,679,000  
Property and equipment impairment   1,259,000   140,412,000 0  
Purchase commitment obligation   116,200,000        
long term purchase commitment | €     € 93.0      
Estimated amounts receivable under program   246,000   743,000 816,000  
Interest cost capitalized   0   100,000 800,000  
Third party logistics            
Summary Of Significant Accounting Policies [Line Items]            
Deferred revenue   1,600,000        
Intellectual property            
Summary Of Significant Accounting Policies [Line Items]            
Total consideration received $ 9,300,000          
Intellectual property sold, net 7,900,000          
Accrued expense associated with intellectual property $ 1,400,000          
Other income (expense)         $ 1,400,000  
Certificates of Deposit            
Summary Of Significant Accounting Policies [Line Items]            
Prepaid expenses and other current assets   350,000   350,000    
Sanofi-Aventis Deutschland GmbH            
Summary Of Significant Accounting Policies [Line Items]            
long term purchase commitment   50,000,000        
Deerfield | Milestone Rights Liability            
Summary Of Significant Accounting Policies [Line Items]            
Long term liability   8,900,000        
Deerfield | Milestone Rights Liability | Senior convertible notes due December 31, 2019            
Summary Of Significant Accounting Policies [Line Items]            
Long term liability   8,900,000   $ 8,900,000   $ 13,100,000
AFREZZA product sales            
Summary Of Significant Accounting Policies [Line Items]            
Product sales revenue gross to net adjustments   $ 800,000        
Product sales revenue gross to net adjustments percentage   30.00% 30.00%      
Minimum | AFREZZA product sales            
Summary Of Significant Accounting Policies [Line Items]            
Sales return right following product expiration in months   6 months 6 months      
Maximum | AFREZZA product sales            
Summary Of Significant Accounting Policies [Line Items]            
Sales return right following product expiration in months   12 months 12 months